Catrin Pritchard's Recent Publications

Publications since 2010
  • Kamata T, Giblett S, Pritchard C (2017) KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment. Blood doi: 10.1182/blood-2017-02-770149.
  • Zou M, Baitei EY, BinEssa H, Al-Mohanna FA, Parhar RS, St-Arnaud R, Kimura S, Pritchard C, Alzahrani AS, Assiri AM, Meyer BF, Shi Y (2017) Cyp24a1 attenuation limits progression of BrafV600E-induced papillary thyroid cancer cells and sensitizes them to BrafV600E inhibitor PLX4720. Cancer Research 77: 2161-2172.
  • Papaioannou G, Petit ET, Liu ES, Baccarini M, Pritchard C, Demay MB (2017) Raf Kinases are Essential for Phosphate Induction of Erk1/2 Phosphorylation in Hypertrophic Chondrocytes and Normal Endochondral Bone Development. Journal of Biological Chemistry 292: 3164-3171.
  • Karekla E, Liao W-J, Sharpe B, Pugh J, Le Quesne J, Moore D, Pritchard C*, MacFarlane M*, Pringle JH (2017) Ex-vivo explant culture of NSCLC provides a relevant pre-clinical model for evaluation of primary tumour responses to anti-cancer therapies. Cancer Research 77: 2029-2039. *Co-corresponding authors.
  • Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ (2016) Inactivation of TGFb receptors in stem cells drives cutaneous squamous cell carcinoma. Nature Communications 7: 12493.
  • Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y (2015) Thyroid stimulating hormone overcomes BrafV600E-induced senescence to promote tumor progression via down-regulation of p53 expression in papillary thyroid cancer. Oncogene 35: 1909-1918.
  • Hey F, Giblett S, Forrest S, Herbert C, Pritchard C (2016) Phosphorylations of serines 21/9 in Glycogen Synthase Kinase a/b are not required for lineage commitment or WNT signaling in the normal mouse intestine. Plos One 11: e0156877.
  • Aguilar Hernandez M, Patel B, Hey F, Giblett S, Davis H, Pritchard C (2016) Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor. Cell Signalling 28: 561-571.
  • Kamata T, Jin H, Giblett S, Patel B, Patel F, Foster C, Pritchard C (2015) The cholesterol binding protein NPC2 restrains recruitment of stromal macrophage-lineage cells to early-stage mouse lung tumours. EMBO Molecular Medicine 7: 1119-1137.
  • Lenos K, Goos JACM, Vuist IM, den Uil SJ, Delis-van Dieman PM, Belt EJT, Stockmann HBAC, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJA, van Vliet SJ (2015) MGL-ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colorectal cancer patients. OncoTarget 6: 26278-26290.
  • Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, BinEssa H, Alanazi AA, Alzahrani AS, Akhtar M, Assiri AM, Meyer BF, Shi Y (2015) KRASG12D mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1. Lab Invest 95: 1269-1277.
  • Althubiti M, Lezina L, Carrera S, Jukes-Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS, Pritchard CA, Cain K, Macip S (2014) Characterisation of novel markers of senescence and their prognostic potential in cancer. Cell Death and Disease 5:e1528.
  • Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C,
    Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee S-M, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L,
    Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C (2014) Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLOS Biology 12: e1001906.
  • Pier DM, Shehatou GSG, Giblett S, Pullar CE, Pritchard CA, Challis RAJ, Mitcheson J (2014) Long-term block is required to inhibit cellular transformation by human ether-a-go-go related gene (hERG1) potassium channels. Molecular Pharmacology 86: 211-221.
  • Hey F and Pritchard C (2013) A new mode of RAF auto-regulation: a further complication in the inhibitor paradox. Cancer Cell. 23: 561-563.
  • Dyer MJS, Vogler M, Samuel J, Jayne S, Wagner S, Pritchard C and Macip S (2013) Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. British Journal of Haematology. 160: 725-733.
  • Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang T-W, Lasitschka F, Andrulis M, Pascual G, Morris J, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman G, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J (2013) A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature Cell Biol. 15: 978-990.
  • Kamata T, Dankort D, Kang J, Giblett S, Pritchard C, McMahon M, Leavitt A (2013) Haemopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res. 11: 1530-1541.
  • Debrand E, Conti FJ, Bate N, Spence L, Mazzeo D, Pritchard CA, Monkley SJ, Critchley DR (2012) Mice carrying a complete deletion of the talin2 coding sequence are viable and fertile. Biochem Biophys Res Comm 426: 190-195.
  • Andreadi C, Cheung L-K, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, Marais R, Pritchard C (2012) The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes and Development 26: 1945-1958.
  • Stringer EJ, Duluc I, Saandi T, Davidson I, Bialecka M, Sato T, Barker N, Clevers H, Pritchard CA, Winton DJ, Wright NA, Freund JN, Deschamps J, Beck F (2012) Cdx2 determines the fate of postnatal intestinal stem cells. Development 139: 465-474.
  • Andreadi CA, Noble C, Patel B, Jin H, Aguilar Hernandez MM, Balmanno K, Cook SJ, Pritchard C (2012) Regulation of MEK/ERK pathway output by subcellular localization of B-Raf. Biochem. Soc. Trans. 40: 67-72.
  • Kamata T, Pritchard C (2011) Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res 1: 955-971.
  • Franco A, Malaguarnera R, Refetoff S, Liao X-H, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies T, Weinstein L, Chen M, Rosen N, Ghossein R, Knauf J, Fagin J (2011) Thyrotrophin receptor signaling-dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci USA 108: 1615-1620.
  • Monkley SJ, Kostourou V, Spence L, Petrich B, Coleman S, Ginsberg MH, Pritchard CA, Critchley DR (2010) Endothelial cell talin1 is essential for embryonic angiogenesis. Dev Biol 349: 494-502.
  • Carragher LAS, Snell KR, Giblett SM, Aldridge VSS, Patel B, Cook SJ, Winton DJ, Marais R, Pritchard CA (2010) V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Molecular Medicine 2: 458-471.
  • Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C (2010) BRAF inactivation drives aneuploidy by deregulating CRAF. Cancer Res 70:8475-8486.
  • Kopp PM, Bate N, Hansen TM, Brindle NBJ, Praekelt U, Debrand E, Coleman S, Mazzeo D, Goult BT, Gingras AR, Pritchard CA, Critchley DR, Monkley SJ (2010) Studies on the morphology and spreading of human endothelial cells define key inter- and intramolecular interactions for talin1. European Journal of Cell Biology 89: 661-673.
  • Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumour progression through CRAF. Cell 140: 209-221.
  • Dhomen N, Da Rocha Dias S, Hayward R, Ogilvie L, Hedley D, Delmas V, Henderson D, Springer CJ, Pritchard C, Larue L, Marais R (2010) Inducible expression of V600EBraf using tyrosinase-driven Cre recombinase results in embryonic lethality. Pigment Cell and Melanoma Research. 23: 112-120.

Share this page:

NEWS

Congratulations from the LCRC to Bethan Rogoyski and Aleksandra Bzura.

Bethan won best oral presentation at the AMS Midlands Academy of Medical Sciences Festival held on 27th March 2019 for her presentation on "Redeployment: The potential of repurposed drugs in preventing mesothelioma".

Aleks won the University PGR poster fair competition on 18th March 2019 for her poster entitled "New hope for treating mesothelioma cancer using PARP inhibitors".

Also, a huge well done to Grandezza Aburido who was in the semi-finals of the PGR poster fair.  

---------------------------------

Congratulations to Noura Alibrahim who passed her PhD viva recently.  Well done!

---------------------------------

In a recent exercise undertaken by the NCRI’s Clinical and Translational Radiotherapy Research Working Group (CTRad) Leicester was rated as internationally competitive/leading in the Radiation Biology Research domain, one of just four centres in the UK to achieve this rating in that domain.

---------------------------------

New: Wellcome Trust Institutional Strategic Support Fund

Details

---------------------------------

Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair jm65@le.ac.uk

Contact Details

Leicester Cancer Research Centre
Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170
E: cancerstudies@le.ac.uk

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 
LE1 5WW

Accessibility

DisabledGo logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.

Seminars

.